AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3236744
Drug: Indomethacin (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (an inhibitor of cyclooxygenase)
Trial: 26360283
Drug: Bespoke smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bespoke smoking cessation strategy (behavioural support and drugs)
Trial: 24342651
Drug: Eravacycline at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eravacycline at 1.5 mg/kg q24h
Trial: 24342651
Drug: Eravacycline at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eravacycline at 1.0 mg/kg q12h
Trial: 24342651
Drug: Ertapenem at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertapenem at 1 g q24h
Trial: 19574947
Drug: Piribedil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piribedil (50 mg for 90 days)
Trial: 17306648
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) - conjugated estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg
Trial: 15105403
Drug: Promegetone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promegetone 0.5 mg plus estradiol 2 mg (E) per day
Trial: 15105403
Drug: Promegetone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promegetone 0.5 mg plus estradiol placebo (PL)
Trial: 8529329
Drug: Intravenous losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous losartan
Trial: 8529329
Drug: Oral losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral losartan
Trial: 2474257
Drug: 2 litres
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 litres of crystalloid solution
Trial: 2474257
Drug: 1 litre
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 litre of colloid solution (hydroxyethyl starch)
Trial: 9377121
Drug: Immediate antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate antiretroviral therapy
Trial: 19020325
Drug: Deferred antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred antiretroviral therapy
Trial: 31416496
Drug: Progressively integrated
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressively integrated sandplay therapy
Trial: 28917373
Drug: Topical Rosa
RxNorm normalized name: Rosa moschata oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Rosa damascena oil
Trial: 21451092
Drug: Various physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various physical therapy interventions
Trial: 19349712
Drug: TTS E2/MPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTS E2/MPA (transdermal estradiol 50 microg + oral medroxyprogesterone acetate 10 mg/day for 12 days)
Trial: 14767865
Drug: Omacor (omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omacor (omega-3 polyunsaturated fatty acid concentrate) 4 capsules daily for 8 weeks
Trial: 8501418
Drug: Cyclosporin (Cs)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin (Cs) treatment at an initial dose of 10 mg kg‐1 BW day‐1 for 12 months
Trial: 8501418
Drug: Cyclosporin (Cs)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin (Cs) treatment
Trial: 3519096
Drug: Low-dose trimipramine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose trimipramine (25 to 75 mg/day)
Trial: 30521639
Drug: Total PBS
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total PBS anticoagulant expenditure
Trial: 29231566
Drug: Moxibustion combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion combined with autohemotherapy of acupoint injection
Trial: 25301344
Drug: Piperacillin 4
RxNorm normalized name: piperacillin 4000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin 4 g with tazobactam 0.5 g intravenously by 1-hour infusion every 8 hours
Trial: 22735756
Drug: RC-3095 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RC-3095 (3 mg/kg, intravenous) administered over a period of 12 h in human patients with sepsis.
Trial: 22735756
Drug: RC-3095 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RC-3095 (3 mg/kg, subcutaneously) in male Wistar rats subjected to cecal ligation and puncture (CLP).
Trial: 22735756
Drug: RC-3095 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RC-3095 (10 ng/mL) in RAW 264.7 culture cells exposed to LPS or TNF-α.
Trial: 15986192
Drug: 0.42 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.42 mg/kg d,l-dexamphetamine
Trial: 22020992
Drug: 0.42 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.42 mg/kg d-methamphetamine
Trial: 15986192
Drug: 0.42 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.42 mg/kg d,l-methamphetamine
Trial: 8535711
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg epirubicin combined with 10 MU alpha 2b‐IFN, intravesically in 50 mL sterile buffer solution
Trial: 8535711
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg epirubicin
Trial: 2243428
Drug: Combined drug
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined drug regimens and diet
Trial: 30458740
Drug: Bitterant formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bitterant formulation
Trial: 30458740
Drug: Perfumed formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perfumed formulation
Trial: 30458740
Drug: Plain formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain formulation
Trial: 27585777
Drug: 50-ppm sodium
RxNorm normalized name: HYPOCHLOROUS ACID 50 [ppm] in 1 mL / SILVER 8 [ppm] in 1 mL TOPICAL SPRAY [OXICLEANSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-ppm sodium fluoride solution
Trial: 23724518
Drug: Gonadotropin treatment
RxNorm normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin treatment and letrozole along with GnRH antagonist protocol (Group 1)
Trial: 23724518
Drug: Gonadotropin treatment
RxNorm normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin treatment along with GnRH antagonist protocol (Group 2)
Trial: 18721002
Drug: Cinacalcet 90
RxNorm normalized name: cinacalcet 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet 90 mg once daily for 5 days
Trial: 18721002
Drug: Midazolam 2
RxNorm normalized name: midazolam 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 2 mg alone
Trial: 8824967
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of diphtheria and tetanus toxoids and pertussis vaccine combined with inactivated poliovirus vaccine
Trial: 1486543
Drug: Pravastatin (hydroxymethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (hydroxymethyl glutaryl coenzyme A reductase inhibitor)
Trial: 23279614
Drug: Once-daily extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily extended-release tacrolimus (LCPT)
Trial: 20143651
Drug: Rupatadine, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rupatadine, 20 mg/d
Trial: 7503601
Drug: Low-dose amphotericin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose amphotericin B (total dose ≤ 500 mg)
Trial: 7503601
Drug: High-dose amphotericin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose amphotericin B (total dose > 500 mg)
Trial: 2048709
Drug: Droperidol 0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 0.075 mg/kg i.v. given at induction of anesthesia after intubation (n = 20)
Trial: 2048709
Drug: Droperidol 0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 0.075 mg/kg i.v. given during the last muscle suture (n = 21)
Trial: 2048709
Drug: No antiemetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiemetic treatment (n = 20)
Trial: 6793303
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of prostaglandin F2 alpha (PGF2 alpha)
Trial: 6793303
Drug: Oral quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral quinine hydrochloride
Trial: 24086259
Drug: Serogroup-C-meningococcal-conjugate-vaccine (partly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serogroup-C-meningococcal-conjugate-vaccine (partly vaccinated villages)
Trial: 19694438
Drug: Yerba mate
RxNorm normalized name: yerba mate
DrugBank: Ilex paraguariensis leaf (DB14366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yerba mate consumption (330 mL, 3 times/day for 40 days) in normolipidemic subjects
Trial: 19694438
Drug: Yerba mate
RxNorm normalized name: yerba mate
DrugBank: Ilex paraguariensis leaf (DB14366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yerba mate intake by dyslipidemic individuals (330 mL, 3 times/day for 40 days)
Trial: 19694438
Drug: Yerba mate
RxNorm normalized name: yerba mate
DrugBank: Ilex paraguariensis leaf (DB14366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yerba mate consumption by hypercholesterolemic individuals on statin therapy (330 mL, 3 times/day for 40 days)
Trial: 17240472
Drug: Telmisartan (20-40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (20-40mg orally once daily for 6 months)
Trial: 3267741
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy (10 sessions of 90 minutes each, led by a psychologist and a general practitioner)
Trial: 31868550
Drug: 0.25ug alfacalcidol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25ug alfacalcidol daily for 3 months
Trial: 25080037
Drug: Test implant
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test implant
Trial: 20919669
Drug: Subcutaneous closed-suction
RxNorm normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous closed-suction drainage (SCSD) applied after fascia closure, removed on postoperative day three.
Trial: 20919669
Drug: No subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No subcutaneous closed-suction drainage (no-drain group).
Trial: 21240151
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR 400 mg/day
Trial: 21240151
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR 600 mg/day
Trial: 21240151
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR 800 mg/day
Trial: 17592906
Drug: Quetiapine IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine IR 400 mg/day
Trial: 2821864
Drug: Ritodrine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritodrine treatment (intravenous, 2 hours prior to operation)
Trial: 2821864
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline (control group, same infusion rate as ritodrine)
Trial: 2663239
Drug: Ketanserin, 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin, 80 mg/day
Trial: 2663239
Drug: Metoprolol, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol, 200 mg/day
Trial: 25583832
Drug: dalfampridine-ER 10
RxNorm normalized name: Dalfampridine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dalfampridine-ER 10 mg twice daily
Trial: 23362895
Drug: General anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia with target-controlled infusion of propofol and remifentanil
Trial: 19114908
Drug: Tight glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight glycemic control (target glycemia, 80‐110 mg/dL)
Trial: 19114908
Drug: Conventional glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glycemic control (control group, target glycemia, 180‐200 mg/dL)
Trial: 15562057
Drug: Propofol-LCT/MCT 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol-LCT/MCT 1% 2 mg/kg IV
Trial: 9329515
Drug: Inhaled formoterol
RxNorm normalized name: formoterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled formoterol 24 micrograms bid for 4 weeks
Trial: 3297528
Drug: Drug-resistant strains
RxNorm normalized name: hepatitis A vaccine (inactivated) strain HM175 Injection [Havrix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-resistant strains
Trial: 25748562
Drug: Cannabidiol (CBD)
RxNorm normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol (CBD) 400 or 800 mg pretreatment with intravenous fentanyl 0.5 μg/kg (session 1) or 1.0 μg/kg (session 2)
Trial: 25748562
Drug: Cannabidiol (CBD)
RxNorm normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol (CBD) 400 or 800 mg pretreatment
Trial: 18845283
Drug: Gynecologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gynecologic treatment plus somatocognitive therapy
Trial: 18845283
Drug: Standard gynecologic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard gynecologic treatment
Trial: 9148356
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (TIVA) with propofol infusion (12 to 6 mg/kg/h)
Trial: 8416664
Drug: Vitamin supplement
RxNorm normalized name: Vitamin supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin supplement (10 mg pyridoxal, 1.0 mg folic acid, 0.4 mg cyanocobalamin)
Trial: 31986170
Drug: NAXOZOL (naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAXOZOL (naproxen 500 mg, esomeprazole strontium tetrahydrate 20 mg) twice per day
Trial: 26338825
Drug: S10 (sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S10 (sequential therapy for 10 days)
Trial: 26338825
Drug: T14 (triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T14 (triple therapy for 14 days)
Trial: 22932084
Drug: Gefarnate 300
RxNorm normalized name: gefarnate
DrugBank: Gefarnate (DB12079)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefarnate 300 mg daily for six weeks
Trial: 22932084
Drug: Sucralfate 3
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucralfate 3 g daily for six weeks
Trial: 12074370
Drug: Medication placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication placebo (PLA)
Trial: 8109654
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of trihexyphenidyl twice daily for 4 weeks
Trial: 775358
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg LHRH nasal spray per day
Trial: 27712095
Drug: Self‐Determination Theory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐Determination Theory (SDT) intervention designed to promote oral health care competence in an autonomy‐supportive way
Trial: 22428137
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg per day oral supplementation and 2 ml (78.9 μM solution) per day topical application of astaxanthin (open-label non-controlled study)
Trial: 22428137
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of astaxanthin daily supplementation (randomized double-blind placebo controlled study)
Trial: 10466845
Drug: BULIT test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BULIT test with long term clinical treatment strategy
Trial: 8830062
Drug: Nefazodone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone (200 mg) administered twice daily from the evening of day 2 to the morning of day 9, with triazolam (0.25 mg) on days 8 and 9.
Trial: 8830062
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered on days 1 and 2, with triazolam (0.25 mg) on days 8 and 9.
Trial: 6235779
Drug: Toxicodendron antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toxicodendron antigen patch test
Trial: 6235779
Drug: Delayed (96-hour)
RxNorm normalized name: Delayed Release Oral Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed (96-hour) patch test reading
Trial: 23400604
Drug: Iron/folic acid
RxNorm normalized name: iron/folic acid 150 mg-1 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron/folic acid (60 mg iron)
Trial: 23400604
Drug: Multiple micronutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrients (30 mg iron)
Trial: 11220045
Drug: Controls (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controls (no medication)
Trial: 11220045
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of pill users with controls
Trial: 20855467
Drug: DHA‐paclitaxel at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA‐paclitaxel at a starting dose of 900 mg/m(2) IV on day 1 every 3 weeks
Trial: 20855467
Drug: Dacarbazine at
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine at a starting dose of 1000 mg/m(2) IV on day 1 every 3 weeks
Trial: 19576297
Drug: Rectal enemas
RxNorm normalized name: Enema
DrugBank: Sodium phosphate, dibasic, unspecified form (DB14504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal enemas (3 enemas/week, reduced by 1 enema/week every 3 months)
Trial: 19576297
Drug: Oral laxatives
RxNorm normalized name: Pedia-Lax Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral laxatives (control group)
Trial: 11710999
Drug: 5 MIU
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 MIU IFN-alpha s.c. daily for 32 consecutive days (IFN-alphaT group)
Trial: 9135948
Drug: sulodexide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulodexide (100 mg/day)
Trial: 7957000
Drug: Codfish (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codfish (1 g fat, 23 g protein per 100 g)
Trial: 7957000
Drug: Walnuts (64
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnuts (64 g fat, 7 g protein, 15 g starch per 100 g)
Trial: 7957000
Drug: Bananas (22
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bananas (22 g starch, 1 g protein per 100 g)
Trial: 29143634
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 3 μg/kg of moxidectin
Trial: 29143634
Drug: Three consecutive
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three consecutive monthly doses of 3 μg/kg of moxidectin
Trial: 21447866
Drug: Detectable viraemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detectable viraemia <15 IU/ml at week 24
Trial: 21447866
Drug: Detectable viraemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detectable viraemia 15-<50 IU/ml at week 24
Trial: 17112296
Drug: Regadenoson (CVT‐3146)
RxNorm normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regadenoson (CVT‐3146) at doses ranging from 0.1 to 30.0 micro g/kg
Trial: 15459410
Drug: Ceftriaxone (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (single dose)
Trial: 16212202
Drug: Ampicillin/cloxacillin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin/cloxacillin (3 doses)
Trial: 11327628
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg, p.o.)
Trial: 11327628
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg, p.o.)
Trial: 3821177
Drug: Aspirin (975
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (975 mg three times daily)
Trial: 3821177
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and ethanol (maximal doses for 3 days)
Trial: 3821177
Drug: Ethanol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (300 ml of 5% or 30 ml of 50% three times nightly)
Trial: 25543421
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of acupuncture and auricular acupressure
Trial: 25543421
Drug: Fluoxetine hydrochloride
RxNorm normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine hydrochloride capsules (20 mg, once a day)
Trial: 24045520
Drug: Timolol plus
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol plus latanoprost (fixed combination therapy)
Trial: 18156457
Drug: Heparin-reduced group
RxNorm normalized name: Heparin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-reduced group (50% reduced standard doses of nonfractionated heparin)
Trial: 18156457
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (full dose of heparin)